From:  A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?

Active trials, both recruiting and not recruiting, testing targets not aforementioned (IDH, FGFR, PARP, HER2, ALK, ROS, and the MAPK pathway)

NCTPhaseStatusTumorsLine of treatmentTargetExperimental treatmentStandard treatmentPrimary endpointsSponsor
NCT044919421RecruitingCCAUNKATR*Cis + BAY 1895344 +/– GemN.A.AEs, RP2DNo-profit
NCT038294361RecruitingCCANTAPPAR-alfa*TPST-1120 +/– nivolumabN.A.DLT, AEs, MTDProfit
NCT044308421RecruitingCCANTALAT1QBS10072SN.A.MTDProfit
NCT041520181RecruitingeCCAUNKIntegrin alpha-V/beta-8*PF 06940434 +/– ITN.A.DLT, AEs, ORR, PFS, DORProfit
NCT034226791/2RecruitingCCANTANOTCH*CB-103N.A.DLT, ORRProfit
NCT039078521/2RecruitingCCA≥ 2 LProtein mesothelinGavo-celN.A.3 months ORRProfit
NCT040681941/2RecruitingCCA and gallbladder cancerNTADNA activated protein kinase (DNA-PK)*NedisertibN.A.MTD, ORRProfit
NCT036337731/2RecruitingiCCA1 LGlycosylated Mucin1MUC-1 CART cell ITN.A.DCRNo-profit
NCT037683752RecruitingeCCA, gallbladder cancer1 LPrecision target therapy based on tumor molecular profilingFORFIRINOX or cetuximab or trastuzumab or gefitinib or lapatinib or everolimus or sorafenib or crizotinibFOLFIRINOXPFSNo-profit
NCT038019152RecruitingCCAPerioperativeCA 19-9 epitopeMVT-5873N.A.1-year recurrence rates, safetyProfit
NCT040342382RecruitingeCCA2 LProtein mesothelinLMB-100 + tofacitinibN.A.Safety, timing of anticorpal responseProfit
NCT043832102RecruitingCCA and gallbladder cancerNTANRG1 gene fusionSeribantumabN.A.ORRProfit
NCT031023201bCompletedCCAUNKProtein mesothelinAnetumab ravtansine + chemotherapyN.A.MTD, ORR, DORProfit
NCT001019721CompletedCCA and gallbladder cancer2–4 LGlycotope RAAG12*RAV12N.A.Toxicity by CTCAEProfit
NCT000205791CompletedCCA and gallbladder cancerNTAHistone deacetylase*EntinostatN.A.DLT, MTD, pharmaco-kineticsNo-profit
NCT000275341CompletedGallbladder cancerReceived prior therapy with possible survival benefit or refused such therapyCEATRICOM-CEA(6D)N.A.Safety and feasibilityNo-profit
NCT028368472UNKeCCA and gallbladder cancer1 LPrecision target therapy based on tumor molecular profilingGEMOX + cetuximab or trastuzumab or gefitinib or lapatinib or everolimus or sorafenib or crizotinibGEMOXPFSNo-profit
NCT048950462Not yet recruitingCCAMaintenanceDefined HRD signatureNiraparib and dostarlimabN.A,PFSProfit
NCT048010951RecruitingCCA1 LpTyr-mtRTKWM-S1-030N.A.MTDProfit
NCT050012821/2Not yet recruitingCCANTAFRα over-expressingELU001N.A.MTD/RP2DProfit
Return to article view

We reported four trials defined as “completed” on www.clinicaltrials.gov, whose results have never been published. Were excluded a “terminate” trial, that is a study stopped early, whose participants are no longer being examined or treated (NCT00012246), and two “withdrawn” trials, stopped early, before enrolling their first participants (NCT01501604 and NCT01859182). *Not inclusion criteria; ATR: ataxia-telangiectasia mutated (ATM) and RAD3-related; LAT: large amino acid transporter; FOLFIRINOX: leucovorin calcium, fluorouracil, irinotecan hydrochloride and oxaliplatin; CA: carbohydrate antigen; NRG1: neuroregulin1; CTCAE: common terminology criteria for adverse events; CEA: carcinoembryonic antigen; HRD: homologous recombination deficency; RTK: receptor tyrosine kinases; FRα: folate receptor alpha